Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Bottles of Corona beer speed past a worker in the bottling line of Mexico City's Modelo brewery, May 19, 2004. REUTERS/Andrew Winning He may be in for worse than a surprise: a nasty skin reaction that one doctor is calling "Mexican beer dermatitis." A substance in lime juice, if left on the skin in the sun, can cause the skin to become discolored, as if by poison ivy or a jellyfish sting and the marks can last for months, reports Scott Flugman in the Archives of Dermatology. Mexican beers, particularly Corona, are typically served with a lime slice wedged in the top of the bottle. The drinker shoves the lime into the bottle and holds his or her thumb over the bottle's mouth while turning the bottle over to mix in the juice. But if the drinker is not careful, the beer's carbonation can spray lime juice and beer all over his or her skin "especially in a patient who is shirtless by a beach or pool," wrote Flugman, a dermatologist in New York. The resulting reaction is due to a substance called psoralen, used to make the skin more sensitive to a wavelength of ultraviolet light, UV-A, used to treat certain skin conditions. Lemons contain psoralens too, but not as strong. "It's just a cosmetic issue," Flugman told Reuters Health, though he said the discoloration most frequently in people like bartenders who work outdoors with limes may take an emotional toll. "People are worried that it's something serious. You might have some brown spots you're been looking at for a few months," he said. Olive-skinned Caucasians may be especially susceptible. No ties have been shown between the reaction and skin cancer, said Flugman, who added that he sees two or three cases a year. They are often mystified why a dermatologist is asking them if they've recently drunk Mexican beer. His advice? "If you do this and you spritz the beer or the lime, just wash it off. Don't leave it on there and sit out in the sun," he said. Or, if you are disinclined to get up for a while, "throw a towel over it."
[A]: Hold the lime with Corona, may cause skin reaction.

[Q]: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. "Based on these data, we plan to open an expanded trial," David Reese, Amgen's head of research and development, said in an interview. "We want to begin exploring quickly enrollment in earlier lines of therapy." Amgen's pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body's immune system can kill the cancer, are a cornerstone of the biotech company's oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies' more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient's own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the "off the shelf" nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.
[A]: Amgen antibody shows promise in myeloma trial, gets FDA fast track.

[Q]: Planned Parenthood, the largest abortion provider in the United States, said its move was spurred by a federal appeals court decision last month clearing the administration's way to restrict Title X grants under a new policy critics have branded a "gag rule." In addition to barring recipients from making abortion referrals, the policy requires financial and physical separation between facilities funded by Title X and those where actual abortions are performed. The rule, imposed by the Department of Health and Human Services (HHS), is part of a broad effort by the Republican president, his allies in Congress and numerous Republican-dominated state legislatures to curtail abortion access in recent years. Planned Parenthood, accounting for about one-fifth of all Title X funds granted, had vowed to cease accepting money from the program months ago, when HHS said it would start enforcing the new restrictions. The group said it would rely instead on private donations and emergency funds to make up the difference as best it could. Monday's move marked a formal Title X withdrawal, to remain permanent unless Congress acts to overturn the restriction or legal challenges prevail in court. "Due to an unethical and dangerous gag rule, the Trump administration has forced Planned Parenthood grantees out of Title 10," Alexis McGill, acting president and CEO of Planned Parenthood, told journalists on a conference call. Planned Parenthood is not alone. Legislatures in Maryland and Massachusetts preemptively adopted measures to opt out of Title X and provide state funding in its place if the new rule took effect. And governors of five other states - Hawaii, Illinois, New York, Oregon and Washington - have said they would do the same. So has Maine Family Planning, a nonprofit, sole recipient of Title X funds in that state. Congress appropriated $286 million in Title X grants in 2017 to Planned Parenthood and other health centers to provide birth control, disease screening and other reproductive health and counseling services to poor women. That funding already was prohibited from being used to pay for abortions, but abortion opponents have long complained that the money in effect subsidized Planned Parenthood as a whole, including its abortion services. The organization had been providing healthcare to about 40% of the 4 million people who rely on Title X funding annually, with 600 of its clinics receiving money from the program. Critics said Planned Parenthood's action showed it was primarily focused on abortion. "In withdrawing from Title X, Planned Parenthood has made it crystal clear that abortion is its number one priority," said Ashley McGuire, a senior fellow with the Catholic Association. Abortion has remained one of the most contentious issues in U.S. politics since the U.S. Supreme Court's landmark 1973 Roe v. Wade decision affirming a woman's constitutional right to terminate her pregnancy. Opponents cite religious beliefs in decrying abortion as immoral, while the other side casts abortion restrictions as infringing on women's private medical choices and control over their own bodies. Federal judges in Washington state, California and Oregon, among nearly two dozen states challenging the administration's rule in court, issued preliminary injunctions against its enforcement earlier this year. But the 9th U.S. Circuit Court of Appeals on June 20 lifted those injunctions, and the same court rejected emergency bids to overturn that decision in July. That allowed the restrictions to take effect while court cases proceed. The rule largely restored a restriction created in 1988 and upheld by the U.S. Supreme Court in 1991, only to be suspended by the Clinton administration in 1993.
[A]:
Planned Parenthood opts out of U.S. subsidies in fight over abortion referrals.